JP2011521969A - 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 - Google Patents
眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 Download PDFInfo
- Publication number
- JP2011521969A JP2011521969A JP2011511843A JP2011511843A JP2011521969A JP 2011521969 A JP2011521969 A JP 2011521969A JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011521969 A JP2011521969 A JP 2011521969A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- kinase
- inhibitor
- activin receptor
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 30
- 208000022873 Ocular disease Diseases 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 108091005735 TGF-beta receptors Proteins 0.000 title abstract 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 title abstract 2
- 206010052428 Wound Diseases 0.000 title abstract 2
- 208000027418 Wounds and injury Diseases 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 238000001356 surgical procedure Methods 0.000 claims abstract description 19
- 230000037390 scarring Effects 0.000 claims abstract description 8
- 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 claims abstract 15
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims abstract 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 33
- 230000019491 signal transduction Effects 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 5
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- 231100000241 scar Toxicity 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 abstract description 13
- 238000001914 filtration Methods 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract 1
- 101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 description 19
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 19
- 210000002950 fibroblast Anatomy 0.000 description 18
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 14
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 14
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 14
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 102000016359 Fibronectins Human genes 0.000 description 7
- 108010067306 Fibronectins Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 6
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 5
- 230000004410 intraocular pressure Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 210000001742 aqueous humor Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000018918 Activin Receptors Human genes 0.000 description 3
- 108010052946 Activin Receptors Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001585 trabecular meshwork Anatomy 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241001469893 Oxyzygonectes dovii Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012122 aqueous mounting media Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5746108P | 2008-05-30 | 2008-05-30 | |
| US61/057,461 | 2008-05-30 | ||
| PCT/US2009/045607 WO2009146408A1 (en) | 2008-05-30 | 2009-05-29 | Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011521969A true JP2011521969A (ja) | 2011-07-28 |
| JP2011521969A5 JP2011521969A5 (enExample) | 2011-09-08 |
Family
ID=41377599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011511843A Pending JP2011521969A (ja) | 2008-05-30 | 2009-05-29 | 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100087486A1 (enExample) |
| EP (1) | EP2285380A4 (enExample) |
| JP (1) | JP2011521969A (enExample) |
| CN (1) | CN102083439A (enExample) |
| WO (1) | WO2009146408A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012524073A (ja) * | 2009-04-17 | 2012-10-11 | スムマ ヘルス システムズ エルエルシー | 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用 |
| WO2012024376A1 (en) * | 2010-08-17 | 2012-02-23 | Allergan, Inc. | Ep2 or ep4 agonists for treating corneal haze |
| MX366336B (es) | 2012-11-02 | 2019-07-05 | Celgene Corp | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. |
| WO2014168264A1 (ja) | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | 肺胞上皮前駆細胞の誘導方法 |
| US9822342B2 (en) | 2013-05-14 | 2017-11-21 | Kyoto University | Method of efficiently inducing cardiomyocytes |
| MX386503B (es) | 2013-07-30 | 2025-03-19 | Kyoto Prefectural Public Univ Corp | Medicamentos terapeuticos de matriz extracelular endotelial corneal. |
| JP6378183B2 (ja) | 2013-08-07 | 2018-08-22 | 国立大学法人京都大学 | 膵ホルモン産生細胞の製造法 |
| CN121136933A (zh) | 2013-09-05 | 2025-12-16 | 国立大学法人京都大学 | 由多能干细胞制造产多巴胺神经前体细胞的方法、产多巴胺神经前体细胞、帕金森病治疗剂和试剂盒 |
| PL3064222T3 (pl) * | 2013-10-31 | 2021-04-19 | Kyoto Prefectural Public University Corporation | Lek terapeutyczny zawierający inhibitor sygnału tgf-beta w chorobach związanych z retikulum endoplazmatycznym i śmiercią komórki w śródbłonku rogówki |
| WO2015178431A1 (ja) | 2014-05-21 | 2015-11-26 | 国立大学法人京都大学 | 膵芽細胞の製造方法および膵芽細胞を含む膵疾患治療剤 |
| CN108697793B (zh) | 2015-11-23 | 2023-08-01 | 阿塞勒隆制药公司 | 治疗眼睛疾病的方法 |
| AU2017254268B2 (en) | 2016-04-22 | 2023-03-16 | Kyoto University | Method for producing dopamine-producing neural precursor cells |
| CN106282092A (zh) * | 2016-09-07 | 2017-01-04 | 山东省眼科研究所 | 一种角膜内皮分离和扩增培养液 |
| KR102594102B1 (ko) | 2017-05-25 | 2023-10-25 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 중간 중배엽 세포로부터 신장 전구 세포로의 분화 유도 방법 및 다능성 줄기세포로부터 신장 전구 세포로의 분화 유도 방법 |
| EP3757208A4 (en) | 2018-02-19 | 2021-12-01 | Sumitomo Dainippon Pharma Co., Ltd. | CELL UNIT, MIXTURE OF CELL UNITS AND METHOD OF MANUFACTURING THEREOF |
| WO2020022261A1 (ja) | 2018-07-23 | 2020-01-30 | 国立大学法人京都大学 | 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法 |
| CA3140384A1 (en) | 2019-05-15 | 2020-11-19 | Ajinomoto Co., Inc. | Method for purifying neural crest cells or corneal epithelial cells |
| JPWO2020235319A1 (enExample) | 2019-05-20 | 2020-11-26 | ||
| WO2021045217A1 (ja) | 2019-09-06 | 2021-03-11 | 学校法人慶應義塾 | グリア前駆細胞を含む細胞凝集体の製造方法 |
| JP7619633B2 (ja) | 2019-10-01 | 2025-01-22 | 国立大学法人京都大学 | 尿管芽先端部細胞の単離方法 |
| JP7785351B2 (ja) | 2020-03-19 | 2025-12-15 | オリヅルセラピューティクス株式会社 | 心筋細胞の精製方法 |
| EP4123015A4 (en) | 2020-03-19 | 2024-05-22 | Orizuru Therapeutics, Inc. | Cardiomyocyte purification method |
| EP4180516A4 (en) | 2020-07-13 | 2024-01-17 | Kyoto University | SKELETON MUSCLE PRECURSOR CELLS AND METHOD FOR PURIFICATION THEREOF, COMPOSITION FOR THE TREATMENT OF MYOGENIC DISEASES AND METHOD FOR PRODUCING SKELETON MUSCLE PRECURSOR CELLS CONTAINING CELL GROUPS |
| JP7798294B2 (ja) | 2021-01-08 | 2026-01-14 | 国立大学法人京都大学 | ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法 |
| EP4353243A4 (en) | 2021-06-10 | 2025-06-25 | Ajinomoto Co., Inc. | METHOD FOR PRODUCING MESENCHYMAL STEM CELLS |
| JPWO2022265086A1 (enExample) | 2021-06-17 | 2022-12-22 | ||
| EP4372075A4 (en) | 2021-07-15 | 2025-06-11 | Cellfiber Co., Ltd. | Structure and use thereof |
| US20240318142A1 (en) | 2021-08-11 | 2024-09-26 | Kyoto University | Method for producing renal interstitial progenitor cells, erythropoietin-producing cells, and method for producing renin-producing cells |
| JPWO2023149407A1 (enExample) | 2022-02-01 | 2023-08-10 | ||
| CN118679244A (zh) | 2022-02-09 | 2024-09-20 | 住友制药株式会社 | 判定培养液中的细胞在由多能干细胞向中脑底板区域的神经系统细胞的分化中的分化能力的方法 |
| WO2023228908A1 (ja) | 2022-05-23 | 2023-11-30 | 国立大学法人京都大学 | 腎集合管細胞および腎盂上皮細胞の製造方法 |
| JPWO2024070494A1 (enExample) | 2022-09-26 | 2024-04-04 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005527590A (ja) * | 2002-04-04 | 2005-09-15 | バイオジェン， インコーポレイテッド | 三置換ヘテロアリールおよびそれらを製造し使用する方法 |
| JP2007533734A (ja) * | 2004-04-21 | 2007-11-22 | アイエヌ２ジェン カンパニー リミテッド | Ａｌｋ５及び／又はａｌｋ４の抑制剤としての２−ピリジル置換イミダゾール類 |
| WO2008006583A1 (en) * | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5470881A (en) * | 1993-09-09 | 1995-11-28 | West Virginia University Research Corporation | Urea ophthalmic ointment and solution |
| US5449671A (en) * | 1993-09-29 | 1995-09-12 | Alcon Laboratories, Inc. | Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery |
| CA2149528A1 (en) * | 1993-09-29 | 1995-04-06 | Billie M. York | Compositions containing growth factors and antimetabolites |
| JPH08503969A (ja) * | 1993-09-29 | 1996-04-30 | アルコン ラボラトリーズ，インコーポレイテッド | 増殖因子と組織形成抑制剤を含有する組成物 |
| US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| US6063396A (en) * | 1994-10-26 | 2000-05-16 | Houston Biotechnology Incorporated | Methods and compositions for the modulation of cell proliferation and wound healing |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| WO2003057670A2 (en) * | 2001-12-28 | 2003-07-17 | Guilford Pharmaceuticals Inc. | Indoles as naaladase inhibitors |
| AU2003300099A1 (en) * | 2003-01-02 | 2004-07-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta |
| DE602004014347D1 (de) * | 2003-03-12 | 2008-07-24 | Millennium Pharm Inc | Chinazolin-derivate als tgf-beta-inhibitoren |
| EP1633718B1 (en) * | 2003-06-17 | 2012-06-06 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s |
| US7098222B2 (en) * | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US20050256118A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US20060234911A1 (en) * | 2005-03-24 | 2006-10-19 | Hoffmann F M | Method of reversing epithelial mesenchymal transition |
| CN101330914A (zh) * | 2005-12-16 | 2008-12-24 | 爱尔康公司 | 使用alk5调节剂控制眼内压 |
| US7524640B2 (en) * | 2006-08-06 | 2009-04-28 | Children's Medical Center Corporation | Inhibiting Smad2/3 signaling promotes neurite outgrowth in dorsal root ganglia |
-
2009
- 2009-05-29 JP JP2011511843A patent/JP2011521969A/ja active Pending
- 2009-05-29 EP EP09755769A patent/EP2285380A4/en not_active Withdrawn
- 2009-05-29 US US12/474,370 patent/US20100087486A1/en not_active Abandoned
- 2009-05-29 CN CN2009801199382A patent/CN102083439A/zh active Pending
- 2009-05-29 WO PCT/US2009/045607 patent/WO2009146408A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005527590A (ja) * | 2002-04-04 | 2005-09-15 | バイオジェン， インコーポレイテッド | 三置換ヘテロアリールおよびそれらを製造し使用する方法 |
| JP2007533734A (ja) * | 2004-04-21 | 2007-11-22 | アイエヌ２ジェン カンパニー リミテッド | Ａｌｋ５及び／又はａｌｋ４の抑制剤としての２−ピリジル置換イミダゾール類 |
| WO2008006583A1 (en) * | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
Non-Patent Citations (5)
| Title |
|---|
| JPN6013041065; Ｌｉｕ Ｘｉｎｇ-Ｊｕｎ ｅｔ ａｌ．: Ｂｉｏｔｅｃｈｎｏｌｏｇｙ ｌｅｔｔｅｒｓ Ｖｏｌ．２７， Ｎｏ．２０, 2005, ｐ．１６０９-１５ * |
| JPN6013041067; Ｔｏｊｏ，Ｍ． ｅｔ ａｌ．: Ｃａｎｃｅｒ ｓｃｉｅｎｃｅ Ｖｏｌ．９６， Ｎｏ．１１, 2005, ｐ．７９１-８００ * |
| JPN6013041069; 雑賀司珠也: 臨床眼科 Ｖｏｌ．６１， Ｎｏ．２, 2007, ｐ．１５６-１６３ * |
| JPN6013041072; 新田信一: あたらしい眼科 Ｖｏｌ．１８， Ｎｏ．１, 2001, ｐ．３-７ * |
| JPN6013041074; 高橋保志: 医薬ジャーナル Ｖｏｌ．３４， 増刊号, 1998, ｐ．２３７-２４２ * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2285380A4 (en) | 2012-03-14 |
| WO2009146408A1 (en) | 2009-12-03 |
| EP2285380A1 (en) | 2011-02-23 |
| CN102083439A (zh) | 2011-06-01 |
| WO2009146408A9 (en) | 2010-12-02 |
| US20100087486A1 (en) | 2010-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011521969A (ja) | 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 | |
| JP7571171B2 (ja) | 翼状片を治療するための組成物及び方法 | |
| JP2012524073A (ja) | 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用 | |
| Morales et al. | Intraoperative mitomycin and corneal endothelium after photorefractive keratectomy | |
| CN109996814B (zh) | 多激酶抑制剂及在眼部纤维化中的用途 | |
| TWI720582B (zh) | ＶＥＧＦ和ＴＧＦβ的多激酶抑制劑及其用途 | |
| CN105050600B (zh) | 眼底疾病治疗剂 | |
| JP7730816B2 (ja) | 過剰血管新生に関連する眼疾患を治療する化合物 | |
| JPH02501483A (ja) | 緑内症または高眼圧症治療剤 | |
| EP3808352A1 (en) | Use of salidroside and derivative thereof in preparation of inhibitor medicament for diseases of ophthalmic fibrosis caused by abnormalities of extracellular matrix proteins | |
| Sapitro et al. | Suppression of transforming growth factor-β effects in rabbit subconjunctival fibroblasts by activin receptor-like kinase 5 inhibitor | |
| KR20010040457A (ko) | 안약 조성물 | |
| WO2014142469A2 (ko) | 안과 염증 질환 치료용 점안제 조성물 및 이의 제조 방법 | |
| JP6861634B2 (ja) | 眼疾患を処置するための組成物及び方法 | |
| JP2016514123A (ja) | ジピリダモールを用いる眼疾患の治療において使用するための組成物 | |
| WO2007050720A1 (en) | Loteprednol etabonate against vascular dysfunction in the eye | |
| Gillies et al. | Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy | |
| WO2019117813A1 (en) | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis | |
| WO2022164996A1 (en) | Methods of treating ocular fibrotic pathologies | |
| Wang et al. | AGTR1 blocker attenuates activation of Tenon's capsule fibroblasts after glaucoma filtration surgery via the NF-κB signaling pathway | |
| TW201717958A (zh) | 眼壓下降增強劑 | |
| Dubey et al. | Management of neovascular glaucoma | |
| JP7580123B2 (ja) | 血管新生関連疾患の予防又は治療用医薬組成物 | |
| KR102068697B1 (ko) | 염증성 안구표면질환의 예방 또는 치료용 조성물 | |
| US8853257B2 (en) | Succinimide derivatives as ocular hypotensive agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110526 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120412 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130828 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140212 |